[go: up one dir, main page]

BRPI0606367A2 - derivados espirocetais e composições farmacêuticas compreendendo os mesmos - Google Patents

derivados espirocetais e composições farmacêuticas compreendendo os mesmos

Info

Publication number
BRPI0606367A2
BRPI0606367A2 BRPI0606367-5A BRPI0606367A BRPI0606367A2 BR PI0606367 A2 BRPI0606367 A2 BR PI0606367A2 BR PI0606367 A BRPI0606367 A BR PI0606367A BR PI0606367 A2 BRPI0606367 A2 BR PI0606367A2
Authority
BR
Brazil
Prior art keywords
optionally substituted
group
derivatives
pharmaceutical compositions
same
Prior art date
Application number
BRPI0606367-5A
Other languages
English (en)
Inventor
Takamitsu Kobayashi
Tsutomu Sato
Masahiro Nishimoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0606367A2 publication Critical patent/BRPI0606367A2/pt
Publication of BRPI0606367B1 publication Critical patent/BRPI0606367B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS ESPIROCETAIS E COMPOSIçõES FARMACêUTICAS COMPREENDENDO OS MESMOS. A presente invenção refere-se a um composto de Fórmula (1): [Fórmula 1] em que R^ 1^, R^ 2^, R^ 3^ e R^ 4^ são cada qual independentemente selecionados de um átomo de hidrogênio, um grupo 01-06 alquila opcionaímente substituida, um grupo C~ 7~-C~ 1-4~ aralquila opcionalmente substituida e -C(=O)Rx; Rx representa um grupo C~ 1~-C~ 6~ alquila opcionalmente substituida, um grupo arila opcionaímente substituida, um grupo heteroarila opcionalmente substituida, um grupo C~ 1~-C~ 6~ alcóxi opcionaímente substituído ou -NReRf; Ar^ 1^ representa um anel carbocíclico aromático opcionalmente substituído ou um anel heterociclico aromático opcionalmente monossubstituído; O representa (CH~ 2~)m(L)p-ou (L)~ p~(CH~ 2~)m; m representa um número inteiro selecionado de O a 2, n representa um número inteiro selecionado de 1 e 2, e p representa um número inteiro selecionado de O e 1; L representa -O-, -S- ou -NR^ 5^-; e A representa um grupo arila opcionalmente substituida ou um grupo heteroarila opcionalmente substituida, um pró-fármaco do mesmo e um saí farmaceuticamente aceitável do mesmo, bem como uma preparação farmacêutica ou composição farmacêutica compreendendo tal composto.
BRPI0606367-5A 2005-01-28 2006-01-27 Compostos derivados espirocetais, bem como composições farmacêuticas e uso dos mesmos BRPI0606367B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005-020901 2005-01-28
JP2005020901 2005-01-28
JP2005-176690 2005-06-16
JP2005176690 2005-06-16
PCT/JP2006/301284 WO2006080421A1 (ja) 2005-01-28 2006-01-27 スピロケタール誘導体、およびその糖尿病治療薬としての使用

Publications (2)

Publication Number Publication Date
BRPI0606367A2 true BRPI0606367A2 (pt) 2009-06-23
BRPI0606367B1 BRPI0606367B1 (pt) 2023-03-21

Family

ID=36740445

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606367-5A BRPI0606367B1 (pt) 2005-01-28 2006-01-27 Compostos derivados espirocetais, bem como composições farmacêuticas e uso dos mesmos

Country Status (23)

Country Link
US (1) US7767651B2 (pt)
EP (2) EP3072897B1 (pt)
JP (1) JP4093587B2 (pt)
KR (2) KR20130102648A (pt)
AR (1) AR054612A1 (pt)
AU (1) AU2006209523B2 (pt)
BR (1) BRPI0606367B1 (pt)
CA (1) CA2596235C (pt)
CR (1) CR9314A (pt)
DK (1) DK1852439T3 (pt)
ES (1) ES2567439T3 (pt)
HR (1) HRP20160333T1 (pt)
HU (1) HUE027078T2 (pt)
IL (1) IL184838A (pt)
MA (1) MA29272B1 (pt)
MY (1) MY140528A (pt)
NO (1) NO341263B1 (pt)
NZ (1) NZ556343A (pt)
PL (1) PL1852439T3 (pt)
RU (1) RU2416617C2 (pt)
SI (1) SI1852439T1 (pt)
TW (1) TW200637869A (pt)
WO (1) WO2006080421A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2019679B1 (en) * 2006-05-23 2018-06-20 Theracos, Inc. Glucose transport inhibitors and methods of use
TWI403516B (zh) * 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
MX2009003927A (es) 2006-10-13 2009-04-23 Chugai Pharmaceutical Co Ltd Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
US7795228B2 (en) 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
BRPI0815708B8 (pt) 2007-08-23 2021-05-25 Theracos Sub Llc composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
ES2526930T3 (es) 2008-05-22 2015-01-16 Astrazeneca Ab Método para el tratamiento de la hiperuricemia empleando un inhibidor de SGLT2 y composición que contiene el mismo
TW201011043A (en) 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
DK2324002T3 (en) 2008-08-22 2016-12-19 Theracos Sub Llc Methods of making of sglt2 inhibitors
EP2334687B9 (en) * 2008-08-28 2012-08-08 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
PT2395983T (pt) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
KR101426180B1 (ko) * 2009-11-02 2014-07-31 화이자 인코포레이티드 디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
JP5711669B2 (ja) * 2009-12-18 2015-05-07 中外製薬株式会社 スピロケタール誘導体の製造方法
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
JP6294665B2 (ja) * 2011-02-25 2018-03-14 中外製薬株式会社 スピロケタール誘導体の結晶
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
TW201400495A (zh) * 2012-04-03 2014-01-01 Daiichi Sankyo Co Ltd 具有螺環之ｃ－醣苷衍生物
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
AU2014370847B2 (en) 2013-12-27 2020-02-20 Chugai Seiyaku Kabushiki Kaisha Solid preparations containing tofogliflozin and process of producing the same
US10346562B2 (en) * 2014-08-21 2019-07-09 Dassault Systèmes Canada Inc. Automated curvature modeling of polygonal lines
CN106317068A (zh) * 2015-06-23 2017-01-11 中国科学院上海药物研究所 一种c,o-螺环芳基糖苷类化合物及其制备和应用
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
AU2018206907B2 (en) 2017-01-11 2023-11-02 Kowa Company, Ltd. Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
CN111989103A (zh) 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
PE20210644A1 (es) 2018-07-19 2021-03-23 Astrazeneca Ab METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US12178809B2 (en) 2018-10-29 2024-12-31 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
JP7776430B2 (ja) 2020-03-06 2025-11-26 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ－１依存性巣状分節性糸球体硬化症を治療する方法
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
JP2023536009A (ja) 2020-07-27 2023-08-23 アストラゼネカ・アクチエボラーグ ダパグリフロジンによる慢性腎疾患の処置方法
AU2022251165A1 (en) 2021-04-01 2023-11-09 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
JP2025503136A (ja) 2022-01-26 2025-01-30 アストラゼネカ・アクチエボラーグ 前糖尿病の治療又は２型糖尿病の発症リスクを低減する際に使用するためのダパグリフロジン
TW202525278A (zh) 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
JP2762903B2 (ja) 1992-11-12 1998-06-11 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
DK0850948T3 (da) * 1996-12-26 2002-07-29 Tanabe Seiyaku Co Propiophenonderivater og fremgangsmåde til fremstilling deraf
JP3055135B2 (ja) 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
UA71994C2 (en) 1999-08-31 2005-01-17 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives, a pharmaceutical composition containing these derivatives and intermediate compounds for the preparation thereof
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6284906B1 (en) 1999-10-12 2001-09-04 University Of Southern California Cyclotrisiloxanes, new siloxane polymers and their preparation
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6627611B2 (en) 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
EP1270584B1 (en) 2000-03-17 2005-12-07 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
EA005994B1 (ru) 2000-09-29 2005-08-25 Киссеи Фармасьютикал Ко., Лтд. Производные глюкопиранозилоксибензилбензола и содержащие их лекарственные композиции
JP3915116B2 (ja) 2000-11-02 2007-05-16 味の素株式会社 新規ピラゾール誘導体及びそれらを含有する糖尿病治療薬
US7053060B2 (en) 2000-11-30 2006-05-30 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
KR100701437B1 (ko) 2000-12-28 2007-03-30 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체 및 그 의약 용도
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US7087579B2 (en) 2001-02-26 2006-08-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
ES2350084T3 (es) 2001-02-27 2011-01-18 Kissei Pharmaceutical Co., Ltd. Derivados de glucopiranosiloxipirazol y uso médico de los mismos.
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
DE60209343T2 (de) 2001-04-11 2006-10-26 Bristol-Myers Squibb Co. Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
CA2672001A1 (en) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
WO2002098893A1 (en) 2001-05-30 2002-12-12 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
WO2003000712A1 (en) 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
JPWO2003011880A1 (ja) 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
JP4424203B2 (ja) 2002-04-26 2010-03-03 味の素株式会社 糖尿病予防・治療剤
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
BR0310006A (pt) 2002-08-09 2005-02-15 Taisho Pharmaceutical Co Ltd Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CA2509835A1 (en) 2002-12-25 2004-07-15 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof
BR0317929A (pt) * 2003-01-03 2006-04-11 Bristol Myers Squibb Co métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
WO2004080990A1 (ja) 2003-03-14 2004-09-23 Astellas Pharma Inc. Ｃ－グリコシド誘導体又はその塩
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
WO2004089966A1 (ja) 2003-04-01 2004-10-21 Taisho Pharmaceutical Co., Ltd. 選択的なヘテロアリール ５－チオ－β－Ｄ－アルドヘキソピラノシドの製造法
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
JP4708187B2 (ja) 2003-06-20 2011-06-22 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
AR048377A1 (es) 2003-08-01 2006-04-26 Janssen Pharmaceutica Nv Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
EA010655B1 (ru) 2003-08-01 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индазол-о-глюкозиды
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
CA2549015A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
EA015104B1 (ru) 2003-08-01 2011-06-30 Мицубиси Танабе Фарма Корпорейшн Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
CA2549025A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
JP4520988B2 (ja) 2003-08-26 2010-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシルオキシ−ピラゾール、これらの化合物を含む医薬組成物、これらの使用及びこれらの調製方法
US8258105B2 (en) 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
DE10361133A1 (de) 2003-12-22 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP2005247834A (ja) 2004-02-04 2005-09-15 Taisho Pharmaceut Co Ltd ナトリウム依存性グルコース供輸送体２の活性阻害剤
BRPI0508259A (pt) 2004-03-04 2007-07-31 Kissei Pharmaceutical derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
US7375113B2 (en) 2004-03-04 2008-05-20 Kissei Pharmaceutical Co., Ltd. Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
WO2005085265A1 (ja) 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
JP4181605B2 (ja) 2004-03-16 2008-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
TW200602335A (en) 2004-03-31 2006-01-16 Kissei Pharmaceutical Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
WO2005095429A1 (ja) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. フェノール誘導体、それを含有する医薬組成物及びその医薬用途
JPWO2005095372A1 (ja) 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
PL1852439T3 (pl) 2016-10-31
RU2416617C2 (ru) 2011-04-20
EP1852439B1 (en) 2016-03-23
NO341263B1 (no) 2017-09-25
CA2596235A1 (en) 2006-08-03
HUE027078T2 (en) 2016-08-29
ES2567439T3 (es) 2016-04-22
WO2006080421A1 (ja) 2006-08-03
AR054612A1 (es) 2007-07-04
EP3072897B1 (en) 2019-06-26
TWI377211B (pt) 2012-11-21
TW200637869A (en) 2006-11-01
KR101322980B1 (ko) 2013-10-29
SI1852439T1 (sl) 2016-06-30
KR20130102648A (ko) 2013-09-17
HRP20160333T1 (hr) 2016-05-06
HK1111999A1 (en) 2008-08-22
NO20074310L (no) 2007-10-29
RU2007132448A (ru) 2009-03-10
MY140528A (en) 2009-12-31
AU2006209523B2 (en) 2011-06-02
DK1852439T3 (en) 2016-05-02
EP1852439A4 (en) 2010-01-13
KR20070101364A (ko) 2007-10-16
AU2006209523A1 (en) 2006-08-03
NZ556343A (en) 2010-01-29
IL184838A0 (en) 2007-12-03
US20090030006A1 (en) 2009-01-29
JP4093587B2 (ja) 2008-06-04
BRPI0606367B1 (pt) 2023-03-21
MA29272B1 (fr) 2008-02-01
CA2596235C (en) 2014-09-16
IL184838A (en) 2012-02-29
US7767651B2 (en) 2010-08-03
EP1852439A1 (en) 2007-11-07
JPWO2006080421A1 (ja) 2008-06-19
EP3072897A1 (en) 2016-09-28
CR9314A (es) 2007-10-04

Similar Documents

Publication Publication Date Title
BRPI0606367A2 (pt) derivados espirocetais e composições farmacêuticas compreendendo os mesmos
ECSP066667A (es) Derivados de ciclohexano espirociclicos
EP2017278A4 (en) DIHYDROPYRAZOLOPYRIMIDINONDERIVAT
ATE556058T1 (de) 1-(2h)-isochinolonderivat
BRPI0509471A (pt) lipìdios, complexos de lipìdio e uso dos mesmos
BRPI0908120A8 (pt) Compostos que são inibidores de erk, composição faramacêutica e uso
WO2008081096A3 (fr) Derives quinolinyliques, leur procede de preparation. les compositions pharmaceutiques qui les contiennent et leur utilisation comme agents hypoglycemiants et hypoli pemiants
WO2008108386A1 (ja) 医薬組成物
TW200612195A (en) Oxime derivatives and the use therof as latent acids
SE0400284D0 (sv) Novel compounds
BRPI0606895A2 (pt) novos compostos com efeito terapêutico
AR020032A1 (es) Derivados de 1,3 -metil eritromicina.
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
TW200612920A (en) Novel imidazolidine derivatives
BR0314363A (pt) Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BRPI0408204A (pt) derivados de quinolinona/benzoxazinona e usos dos mesmos
BR0212673A (pt) Espirocìclicas-6,7-dihidro-5h-pirazolo[1,2a]pirazol-1- onas e composição farmacêutica compreendendo as mesmas
CY1117026T1 (el) Ετεροκυκλικες ενωσεις για αντιμετωπιση ή προληψη διαταραχων που προκαλουνται απο μειωμενη νευροδιαβιβαση σεροτονινης, νορεπινεφρινης ή ντοπαμινης
BRPI0508102A (pt) inibidores de caspase e usos dos mesmos
WO2007017728A3 (en) Novel heterocyclic compounds
WO2009019721A3 (en) Quercetin derivatives as anti-cancer agents
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.